[Ip-health] Public Citizen Response to Lilly CEO's Forbes op-ed on TTIP
sknievel at citizen.org
Fri Sep 19 12:31:09 PDT 2014
Apologies for cross-posting
Pharmaceutical CEO: This Controversial Deal Will Be Great for Us.And You (Trust Us)
In an op-ed appearing in Forbes on Tuesday, the CEO of Eli Lilly, a U.S. pharmaceutical corporation, paints a glowing picture of how the proposed Trans-Atlantic Free Trade Agreement (TAFTA) would benefit consumers on both sides of the Atlantic - but it's pure fantasy.
It is not surprising that Eli Lilly is cheerleading this controversial deal. This is the same pharmaceutical firm that is using the North American Free Trade Agreement (NAFTA) - TAFTA's predecessor - to challenge Canada's legal standards for granting patents and demand $500 million in taxpayer compensation.
John Lechleiter, Lilly's CEO, shrouds his arguments under the guise of "free trade," while in reality Lilly's TAFTA proposals are a plea for increased government protection for his company and expansion of the monopolistic business model upon which the multinational pharmaceutical industry relies.
This post will take on Mr. Lechleiter's claims, one by one.
Organizer | Global Access to Medicines Program
Public Citizen | Protecting Health, Safety and Democracy
TEL: +1 202-588-7769
1600 20th St. NW, Washington, DC 20009
More information about the Ip-health